Financial Performance - Revenue increased by 30% to $65309 million in Q2 2025[18], driven by a 39% increase in the average gold price to $3186/oz[18] - Net profit attributable to shareholders of the Company rose by 147% to $20487 million in Q2 2025[18] - Adjusted earnings per share increased by 155%[16] - Operating cash flow increased to $281 million[16] - The company's net cash position was $82 million, excluding $18 million in fixed term deposits[16] Operational Highlights - Blanket Mine production increased to 21442 ounces in Q2 2025[18], a 1% increase compared to Q2 2024[18] - Full-year production guidance for Blanket Mine was raised to 75500–79500 ounces[16] - Blanket Mine's on-mine cost per ounce increased by 44%[30] - Blanket Mine's AISC per ounce increased by 74%[32] Strategic Initiatives - The solar plant was sold for $224 million[13] - Exploration program underway at Motapa, with diamond drilling of 178798 meters and reverse circulation drilling of 9638 meters completed[59] - The company is exploring cost-saving and phasing options for the Bilboes feasibility study[16] Reporting Changes - Caledonia will no longer publish quarterly financial statements and MD&A reports[41]

Financial Performance - In Q2 2025, total revenues were US$194 million [9], a decrease of 133% year-over-year [45] - Net income for Q2 2025 was US$07 million [9] - Non-Mainland China revenue contribution was 668% in Q2 2025 [42] - Gross margin from services is consistently higher than overall gross margin [50] Business Strategy and Highlights - The company is accelerating three transformative lines: GlocalMe Life, SIM, and IoT, investing in R&D, go-to-market strategies, and brand building [11] - The company is fortifying its traditional line, GlocalMe MBB, offsetting tariff uncertainty and supply chain adjustments [11] - PetPhone is undergoing global expansion with launches and branding in several countries in Q3 2025 and potential partnerships with over 20 strategic partners [16] - eSIM TRIO has sold over 300,000 units from Q1 2024 to Q2 2025, establishing a competitive advantage in the market [24] - GlocalMe IoT is experiencing rapid growth, with a 10+ times year-over-year growth in Average Daily Active Terminals (DAT) [32] Operational Metrics - Daily Active Terminals (DAT) for uCloudlink 20 increased from 43% in Q2 2024 to 45% in Q2 2025 [37] - In Q2 2025, IoT accounted for 27% of the DAT breakdown, while SIM accounted for 30%, Life for 15% and MBB for 28% [37]

Financial Performance - Q2 2025 revenue was $138.1 million, a 0.1% increase year-over-year[26, 48] - GAAP gross margin was 43.1% in Q2 2025, a decrease of 0.7% compared to Q2 2024's 43.8%[30, 48] - Non-GAAP gross margin was 47.7% in Q2 2025, a decrease of 1.3% compared to Q2 2024's 49.0%[30, 48] - GAAP operating loss improved to $16.6 million in Q2 2025 from $26.0 million in Q2 2024[36, 48] - Non-GAAP operating income was $1.1 million in Q2 2025, compared to a loss of $3.2 million in Q2 2024[36, 48] - GAAP net loss improved to $16.7 million in Q2 2025 from $25.7 million in Q2 2024[36, 48] - Non-GAAP net income was $2.2 million in Q2 2025, compared to a loss of $3.0 million in Q2 2024[36, 48] Balance Sheet and Cash Flow - The company's cash and cash equivalents and short-term deposits were $254.6 million in Q2 2025[39] - Net working capital was $448.8 million in Q2 2025[39] - Cash flow from operating activities was negative $1.1 million in Q2 2025[38] Outlook - The company expects full-year 2025 revenue between $550 million and $560 million[42] - The company expects full-year 2025 non-GAAP gross margins between 46.7% and 47.0%[42] - The company expects full-year 2025 non-GAAP operating expenses between $248 million and $251 million[42]

Transaction Overview - Gildan will acquire all outstanding shares of HanesBrands for 0.102x Gildan shares and $0.80 cash per HanesBrands share[32] - The implied value is $6.00 per HanesBrands share, representing an implied premium of approximately 24%[32] - The total enterprise value is $4.4 billion, implying an 8.9x LTM adjusted EBITDA multiple, or 6.3x on a fully synergized basis[32] - Upon closing, HanesBrands shareholders will own approximately 19.9% of Gildan shares on a non-diluted basis[32] Financial Highlights - The LTM pro forma revenue is $6.9 billion; LTM pro forma adjusted EBITDA is approximately $1.6 billion, including expected run-rate cost synergies of $200 million[32] - Gildan expects to realize at least $200 million of annual run-rate cost synergies within 3 years of closing, with approximately $50 million to be realized in 2026, approximately $100 million in 2027, and approximately $50 million in 2028[32, 51] - Gildan's adjusted diluted EPS CAGR over the next three years is expected to be in the low 20% range, starting from the midpoint of Gildan's 2025 adjusted diluted EPS guidance[32] - The expected closing net debt leverage ratio is 2.6x; the expected net debt leverage ratio is less than 2.0x within 12 to 18 months post-closing, in line with the stated long-term target net debt leverage ratio of 1.5x – 2.5x[32] Strategic Review - Gildan intends to initiate a review of strategic alternatives for the HanesBrands Australia business ("HAA") post-closing[32]

Q2 2025 Financial Highlights - Q2 2025 revenue reached $71.0 million[8], showing a year-over-year growth of 17%[8] - The company's annualized revenue, calculated as Q2 2025 revenue multiplied by 4, is $284 million[8] - Remaining Performance Obligations (RPO) totaled $273.8 million[8], with 68%[8] expected to be recognized over the next 12 months[8] - Non-GAAP gross margin for Q2 2025 was 81%[8] - The dollar-based net retention rate (NRR) for Q2 2025 was 108%[8] - 63%[8] of the total ARR comes from customers with over $100K+ ARR[8] - 57%[8] of ARR is from multi-year subscriptions[8] Business Model and Market Opportunity - The company estimates its addressable market to be $55 billion[42] - The company's sales and marketing spend is approximately 45% to 50% for customer acquisition and 50% to 55% for customer retention[75]

Investor Presentation August 2025 2Q2025 Disclaimer This presentation contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's financial pe ...

Financial Performance - Revenue increased by 22% to $95.6 million in Q2 2025, compared to $78.1 million in Q2 2024[26,32] - Recurring revenue grew by 32% to $70.7 million, representing 74% of total revenue in Q2 2025[26,32,39] - Gross margin increased to 48.3% from 44.3% due to processing margin improvements and supply chain optimization[26,32] - Adjusted EBITDA increased by 56% to $12.6 million, representing 13% of total revenue, compared to $8.1 million in Q2 2024[26,32,59] - Transaction value processed increased by 34% to $1.59 billion[26,32] Customer and Device Growth - The number of customers increased by 24% to nearly 105,000[26,32] - Managed and connected devices increased by 16% to 1.38 million[26,32] Strategic Developments - A strategic partnership with Autel Energy was announced to embed the company's payment technology into approximately 100,000 Autel chargers across North America and Europe by the end of 2026[33] - The company acquired the remaining 51% of Nayax Capital, consolidating it under the embedded finance division[33] Future Outlook - The company projects revenue between $410 million and $425 million for FY 2025[37,62] - The company is reaffirming 2028 outlook of 35% annual revenue growth and a target of 30% Adjusted EBITDA[64]

Financial Performance - Q2 2025 revenues reached $20.1 million [9], while gross margin was 21.4% [9] - The company raised $15 million in bank debt at favorable rates and terms [9] - Q2 2025 revenue increased by 22.4% year-over-year compared to Q2 2024 [27] - Adjusted EBITDA for Q2 2025 was $(8.7) million, a year-over-year growth of -$4.8 million [27] - The company reaffirms full year 2025 revenue guidance of $130-140 million, representing a 26-35% year-over-year growth [9, 34] Backlog and Pipeline - Purchase order backlog reached $43 million, up $7 million [9] - The company has a contracted backlog of $409 million minimum revenue expected to realize over 10 years [17] - The company expects to realize over $1 billion in contracted & uncommitted revenue over 10 years [17] - Over 80% of 2024 revenues are recurring in nature [25] Segment Performance - Aeronautics revenue for Q2 2025 was $6.9 million, a decrease of 31.7% year-over-year [30] - Architecture revenue for Q2 2025 was $2.5 million, a decrease of 5.2% year-over-year [30] - Automotive revenue for Q2 2025 was $1.4 million, an increase of 54.1% year-over-year [30] - Safety-Tech revenue for Q2 2025 was $9.3 million, a decrease of 14.1% year-over-year [30]

Financial Performance - Okeanis Eco Tankers reported a fleetwide TCE of $50,500 per day in Q2 2025, compared to $64,900 in 6M 2024 [16] - Adjusted EBITDA for Q2 2025 was $473 million, versus $639 million in Q2 2024 [16] - The company's adjusted profit was $267 million in Q2 2025, compared to $397 million in Q2 2024 [16] - Adjusted EPS was $083 in Q2 2025, compared to $123 in Q2 2024 [16] - TCE revenue reached $640 million in Q2 2025 and $1126 million for the first half of 2025 [16, 21] Balance Sheet and Capital Structure - Total debt stood at $6309 million in Q2 2025 [16] - Total cash was $653 million in Q2 2025 [16] - Total assets amounted to $10831 billion in Q2 2025 [16] - Total equity was $4283 million in Q2 2025 [16] - The company's book leverage was 57% in Q2 2025 [16] Fleet and Commercial Operations - VLCC TCE was $49,800 per day and Suezmax TCE was $51,400 per day in Q2 2025 [16] - For Q3 2025 guidance, 77% of available VLCC spot days are fixed at $44,200 per day, and 60% of available Suezmax spot days are fixed at $34,200 per day [37]

Emi-Le (XMT-1660) Clinical Development - Mersana is advancing Emi-Le to address the high unmet need in post-Topo-1 TNBC, with over 40 patients enrolled in the expansion phase at two doses and plans to present initial expansion data in the second half of 2025[5] - Confirmed objective responses were observed across various tumor types including HR+BC, endometrial cancer, ovarian cancer, and ACC-1[5] - In the intermediate dose range, an ORR of 31% (8/26) was observed in evaluable patients with B7-H4 high tumors, including a 23% (3/13) ORR in TNBC and a 50% (2/4) ORR in endometrial cancer[55] - In evaluable patients with B7-H4 high post-Topo-1 TNBC in the intermediate dose range, the confirmed ORR was 23% (3/13), and 29% (2/7) in patients with ≤4 prior lines of therapy[58] - Preliminary data in the high dose range suggest potential for even greater clinical activity, with 7 out of 11 evaluable patients achieving tumor reductions of ≥30% at doses >674 mg/m2[67] XMT-2056 and Platform Collaborations - XMT-2056, an Immunosynthen STING agonist HER2 ADC, is in Phase 1 dose escalation, with plans to present initial clinical pharmacodynamic STING activation data in 2025[5] - Mersana has a global license option agreement with GSK plc for XMT-2056[5] - Mersana has a Dolasynthen research collaboration with Johnson & Johnson and an Immunosynthen research collaboration with Merck KGaA, Darmstadt, Germany[5] Safety and Tolerability - Emi-Le was observed to be generally well-tolerated, with any treatment-related adverse event (TRAE) occurring in 830% (117/141) of patients, Grade 3 TRAEs in 369% (52/141), and TRAEs leading to treatment discontinuation in 35% (5/141)[43] - The most common TRAEs were transient AST increase, generally asymptomatic and reversible proteinuria, generally low-grade fatigue and nausea[47] Market Opportunity - The global relapsed/refractory TNBC market is projected to exceed $1 billion annually starting in 2025[28] ACC-1 Clinical Activity - In patients with ACC-1, the ORR was 556% (5/9) across all doses, unselected for B7-H4 expression[94]